Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Bergsma, 2017, Radiotherapy for oligometastatic lung cancer, Front Oncol, 19, 7 Hendriks, 2015, Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non–small cell lung cancer: results from a population-based study, Eur J Cancer, 51, 2534, 10.1016/j.ejca.2015.08.008 De Ruysscher, 2012, Radical treatment of non–small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450), J Thorac Oncol, 7, 1547, 10.1097/JTO.0b013e318262caf6 Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0 Iyengar, 2018, Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial, JAMA Oncol, 4, e173501, 10.1001/jamaoncol.2017.3501 Gettinger, 2018, Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study, J Clin Oncol, 36, 1675, 10.1200/JCO.2017.77.0412 Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer, N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Ngwa, 2018, Using immunotherapy to boost the abscopal effect, Nat Rev Cancer, 18, 313, 10.1038/nrc.2018.6